MX346312B - Tratamientos oftalmicos. - Google Patents
Tratamientos oftalmicos.Info
- Publication number
- MX346312B MX346312B MX2013011314A MX2013011314A MX346312B MX 346312 B MX346312 B MX 346312B MX 2013011314 A MX2013011314 A MX 2013011314A MX 2013011314 A MX2013011314 A MX 2013011314A MX 346312 B MX346312 B MX 346312B
- Authority
- MX
- Mexico
- Prior art keywords
- eye
- compositions
- pharmaceuticals
- tramadol
- analgesic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1105731.2A GB201105731D0 (en) | 2011-04-05 | 2011-04-05 | Topical analgesics |
| GBGB1105732.0A GB201105732D0 (en) | 2011-04-05 | 2011-04-05 | Ophthalmic lubricants |
| PCT/GB2012/000330 WO2012136969A2 (en) | 2011-04-05 | 2012-04-05 | Ophthalmic treatments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013011314A MX2013011314A (es) | 2014-03-27 |
| MX346312B true MX346312B (es) | 2017-03-15 |
Family
ID=46086008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013011314A MX346312B (es) | 2011-04-05 | 2012-04-05 | Tratamientos oftalmicos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140088199A1 (OSRAM) |
| EP (2) | EP3799866A1 (OSRAM) |
| JP (2) | JP6148664B2 (OSRAM) |
| KR (2) | KR20140145948A (OSRAM) |
| CN (2) | CN103687594A (OSRAM) |
| BR (1) | BR112013025493A2 (OSRAM) |
| CA (1) | CA2869280C (OSRAM) |
| ES (1) | ES2836808T3 (OSRAM) |
| HK (1) | HK1254720A1 (OSRAM) |
| MA (1) | MA35070B1 (OSRAM) |
| MX (1) | MX346312B (OSRAM) |
| WO (1) | WO2012136969A2 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103687594A (zh) * | 2011-04-05 | 2014-03-26 | 奥普托索夫有限公司 | 眼科治疗 |
| GB201217522D0 (en) * | 2012-10-01 | 2012-11-14 | Sharma Anant | ophthalmic therapy |
| WO2014167326A1 (en) * | 2013-04-09 | 2014-10-16 | Cresset Biomolecular Discovery Ltd | The local treatment of inflammatory ophthalmic diseases |
| ES2540151B1 (es) * | 2013-10-11 | 2016-02-29 | Farmalider S.A. | Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico |
| RU2549472C1 (ru) * | 2013-12-26 | 2015-04-27 | Илья Александрович Марков | Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз |
| WO2015106068A1 (en) * | 2014-01-10 | 2015-07-16 | Manistee Partners Llc | Treatment of migraines |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US20170232024A1 (en) | 2014-08-04 | 2017-08-17 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| CA2976120A1 (en) * | 2015-02-24 | 2016-09-01 | The Board Of Trustees Of The University Of Illinois | Use of brimonidine for treating dry eye syndrome |
| US9877964B2 (en) | 2015-02-24 | 2018-01-30 | Ocugen, Inc. | Methods and compositions for treating dry eye disease and other eye disorders |
| CN118453493A (zh) | 2015-05-29 | 2024-08-09 | 西德奈克西斯公司 | D2o稳定化的药物制剂 |
| ES2604816B1 (es) | 2015-09-09 | 2018-01-29 | Farmalider, S.A. | Composición farmacéutica de tramadol para uso oftálmico |
| PT3842047T (pt) * | 2015-09-24 | 2024-09-19 | Matrix Biology Inst | Composições de hialuronano de elevada elasticidade e processos para o seu uso |
| US20180344676A1 (en) * | 2015-09-30 | 2018-12-06 | George Edward Hoag | Topical analgesic pain relief formulations, manufacture and methods of use thereof |
| CN105232449B (zh) * | 2015-10-30 | 2019-04-09 | 上海昊海生物科技股份有限公司 | 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法 |
| CA3285799A1 (en) * | 2016-10-12 | 2025-11-29 | Ps Therapy, Inc. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
| JP2020523406A (ja) | 2017-05-19 | 2020-08-06 | オクジェン アイエヌシー． | 眼科用組成物および使用方法 |
| SG11201911750RA (en) * | 2017-06-08 | 2020-01-30 | Eye Therapies Llc | Low-dose brimonidine combinations and uses thereof |
| PT3723739T (pt) | 2017-12-15 | 2024-06-21 | Tarsus Pharmaceuticals Inc | Formulações de parasiticida isoxazolina e sua utilização para o tratamento de blefarite |
| WO2019122982A1 (en) | 2017-12-21 | 2019-06-27 | Grünenthal GmbH | Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment |
| TWI847978B (zh) * | 2018-03-13 | 2024-07-11 | 日商參天製藥股份有限公司 | 點眼型洗眼藥用組合物 |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| FR3096890B1 (fr) * | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| CA3143071A1 (en) | 2019-07-26 | 2021-02-04 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
| US11504269B2 (en) | 2019-11-19 | 2022-11-22 | Jennifer L. Fabian | Therapeutic bra |
| WO2021163304A1 (en) * | 2020-02-11 | 2021-08-19 | Tufts Medical Center, Inc. | Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation |
| CN112007028A (zh) * | 2020-09-03 | 2020-12-01 | 北京博纳致恒科技有限责任公司 | 一种复合睫状肌松弛剂的人工泪液及用途 |
| US20240139136A1 (en) * | 2021-02-26 | 2024-05-02 | Vyluma Inc. | Methods and formulations for topical administration of gabapentinoids |
| WO2023285878A1 (en) * | 2021-07-13 | 2023-01-19 | Aviation-Ophthalmology | Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions |
| JPWO2024010040A1 (OSRAM) * | 2022-07-06 | 2024-01-11 | ||
| JPWO2024010039A1 (OSRAM) * | 2022-07-06 | 2024-01-11 | ||
| JPWO2024010044A1 (OSRAM) * | 2022-07-06 | 2024-01-11 | ||
| WO2024010045A1 (ja) * | 2022-07-06 | 2024-01-11 | 学校法人金沢医科大学 | 疼痛抑制剤 |
| WO2025146828A1 (ja) * | 2024-01-05 | 2025-07-10 | ロート製薬株式会社 | 眼科組成物 |
| WO2025159099A1 (ja) * | 2024-01-24 | 2025-07-31 | 国立大学法人北海道大学 | 医薬組成物、眼瞼けいれん処置薬、知覚過敏またはジストニア処置薬、および症状モデルマウス |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6384043B1 (en) | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
| US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| DE69711078T2 (de) * | 1996-12-16 | 2002-10-02 | Alcon Laboratories, Inc. | Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz |
| US6174878B1 (en) * | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
| JP2004143157A (ja) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | 点眼剤 |
| US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
| ES2309766T3 (es) | 2004-06-04 | 2008-12-16 | Camurus Ab | Formulaciones liquidas de liberacion lenta. |
| EP1611877A1 (en) * | 2004-06-28 | 2006-01-04 | Universidade de Coimbra | Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs |
| WO2007057508A2 (en) | 2005-11-18 | 2007-05-24 | Orion Corporation | Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol |
| WO2007087609A2 (en) * | 2006-01-25 | 2007-08-02 | Aciex, Inc. | Formulations and methods for treating dry eye |
| MX2009012645A (es) * | 2007-05-24 | 2010-03-08 | Aciex Therapeutics Inc | Formulaciones y metodos para tratar el ojo seco. |
| EP2311446A1 (en) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
| CN103687594A (zh) * | 2011-04-05 | 2014-03-26 | 奥普托索夫有限公司 | 眼科治疗 |
-
2012
- 2012-04-05 CN CN201280025096.6A patent/CN103687594A/zh active Pending
- 2012-04-05 ES ES12721571T patent/ES2836808T3/es active Active
- 2012-04-05 JP JP2014503208A patent/JP6148664B2/ja active Active
- 2012-04-05 US US14/009,397 patent/US20140088199A1/en not_active Abandoned
- 2012-04-05 BR BR112013025493A patent/BR112013025493A2/pt not_active Application Discontinuation
- 2012-04-05 EP EP20200285.3A patent/EP3799866A1/en active Pending
- 2012-04-05 WO PCT/GB2012/000330 patent/WO2012136969A2/en not_active Ceased
- 2012-04-05 CA CA2869280A patent/CA2869280C/en active Active
- 2012-04-05 EP EP12721571.3A patent/EP2694048B1/en active Active
- 2012-04-05 MA MA36378A patent/MA35070B1/fr unknown
- 2012-04-05 MX MX2013011314A patent/MX346312B/es active IP Right Grant
- 2012-04-05 CN CN201711200533.4A patent/CN107982211A/zh active Pending
- 2012-04-05 KR KR1020137029016A patent/KR20140145948A/ko not_active Ceased
- 2012-04-05 KR KR1020187038197A patent/KR102165246B1/ko active Active
-
2016
- 2016-03-21 US US15/076,098 patent/US9913813B2/en active Active
-
2017
- 2017-03-07 JP JP2017043172A patent/JP6419876B2/ja active Active
-
2018
- 2018-10-26 HK HK18113731.7A patent/HK1254720A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9913813B2 (en) | 2018-03-13 |
| CN103687594A (zh) | 2014-03-26 |
| HK1254720A1 (zh) | 2019-07-26 |
| US20160199320A1 (en) | 2016-07-14 |
| KR20190004815A (ko) | 2019-01-14 |
| JP2014513073A (ja) | 2014-05-29 |
| US20140088199A1 (en) | 2014-03-27 |
| KR102165246B1 (ko) | 2020-10-13 |
| WO2012136969A2 (en) | 2012-10-11 |
| EP2694048B1 (en) | 2020-10-07 |
| CA2869280A1 (en) | 2012-10-11 |
| MA35070B1 (fr) | 2014-04-03 |
| WO2012136969A3 (en) | 2013-01-03 |
| BR112013025493A2 (pt) | 2017-03-01 |
| EP2694048A2 (en) | 2014-02-12 |
| JP6148664B2 (ja) | 2017-06-14 |
| ES2836808T3 (es) | 2021-06-28 |
| MX2013011314A (es) | 2014-03-27 |
| KR20140145948A (ko) | 2014-12-24 |
| CA2869280C (en) | 2020-03-10 |
| JP6419876B2 (ja) | 2018-11-07 |
| CN107982211A (zh) | 2018-05-04 |
| JP2017141243A (ja) | 2017-08-17 |
| EP3799866A1 (en) | 2021-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013011314A (es) | Tratamientos oftalmicos. | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| BR112015001158A2 (pt) | formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
| WO2011053801A3 (en) | Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye | |
| EP4371615A3 (en) | Treatment of amd using aav sflt-1 | |
| WO2012063237A3 (en) | Buffered ophthalmic compositions and methods of use thereof | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| RU2013141845A (ru) | Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа | |
| WO2009090624A3 (es) | Gel de quitosano para aplicaciones dermatológicas, proceso de obtención y uso del mismo | |
| EP3653205A3 (en) | Oxymethazoline for topical ophthalmic administration and uses thereof | |
| NZ704247A (en) | Compositions and treatment for eye diseases and disorders | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| NZ706990A (en) | A veterinary method of alleviating noise aversion | |
| MY147864A (en) | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | |
| WO2019118779A3 (en) | Peptides and other agents for treating pain and increasing pain sensitivity | |
| MD20140004A2 (en) | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: OPTOSOLVE RESEARCH & DEVELOPMENT LIMITED |
|
| FG | Grant or registration |